Tobramycin and alpha-dornase treatment for cystic fibrosis (cf) in Uruguay

Publication year: 2010

Objective:

describe the population, evaluate the e-cacy of treatment (lung functionality, nutritional assessment) and adherence.

Methods:

Cohort study of patients who began treatment with Tobramycin and/or Alpha-Dornase from December 2007 to July 2010. Adherence to Tobramycin was measured by an index that relates the number of cycles received/optimal number of cycles, values > 0.8 were considered optimal. Changes in forced expiratory volume in 1st second (FEV1) and body mass index (BMI) were assessed at one year of treatment.

Conclusions:

A delay in the diagnostic was observed comparing with international literature (acceptable during the first year of life). Adherence was good, and lung function improved after one year of treatment and BMI remained stable within acceptable parameters.(AU)